BLRX — BioLineRx Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1498403 ·
Israel
Last close
$3.00
Market Cap
$13.10M
52W High
$3.95
52W Low
$2.60
ADV30
8,650
Next earnings
2026-08-25
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 477,000 | 382,000 | -3,004,000 | -1,601,000 | 38,797,000 | 2,504,000 | 17,962,000 |
| Dec 2025 | 194,000 | 154,000 | -3,386,000 | -1,385,000 | 40,905,000 | 3,250,000 | 17,560,000 |
| Sep 2025 | 427,000 | 343,000 | -2,207,000 | -977,000 | 39,804,000 | 7,914,000 | 20,271,000 |
| Jun 2025 | 304,000 | 232,000 | -2,303,000 | -3,940,000 | 43,267,000 | 7,189,000 | 23,195,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,763,000
Investing CF
$2,335,000
Financing CF
$-1,746,000
CapEx
$-6,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-402,603,000
Inventory
$2,157,000
Receivables
$1,891,000
ST Investments
$14,849,000
EBIT TTM
$-8,660,000
Pretax Income TTM
$-9,741,000
Interest Exp TTM
$1,081,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,402,000
EBITDA
$-10,750,000
Free Cash Flow
$-5,490,125
Enterprise Value
$8,106,314
Total Cash
$17,353,000
Total Debt
$9,070,000
Shares Out
4,368,295
Trailing EPS
$0.00
Book Value
$3.60
ROE
-46.7%
ROA
-16.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,180,000 | -10,287,000 | -1,175,000 | 40,905,000 | 17,560,000 | — | -8,074,000 |
| Dec 2024 | 28,940,000 | -19,152,000 | -9,221,000 | 38,906,000 | 25,445,000 | — | -43,873,000 |
| Dec 2023 | 4,800,000 | -42,991,000 | -60,614,000 | 63,925,000 | 50,702,000 | — | -22,608,000 |
| Dec 2022 | 0 | -29,157,000 | -24,951,000 | 76,384,000 | 25,543,000 | — | -26,240,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.64
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $3.00 · call volume: 2 · put volume: 0
Expected Move to 2027-02-19:
±$3.35
(111.67%) —
implied range
$-0.35 –
$6.35
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BIOE | Bio Essence Corp | $13.45M | $0.25 | — |
| PHIO | Phio Pharmaceuticals Corp. | $13.59M | $1.17 | — |
| GTBP | GT Biopharma, Inc. | $13.79M | $0.31 | — |
| KPRX | KIORA PHARMACEUTICALS INC | $12.17M | $2.75 | — |
| PDSB | PDS Biotechnology Corp | $12.13M | $0.22 | — |
News headlines (Yahoo Finance, 1h cache)
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
2026-08-25 11:00 · Yahoo
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
2026-07-20 11:00 · Yahoo
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
2026-07-08 11:00 · Yahoo
BioLine Rx Ltd (BLRX) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
2026-06-03 01:01 · Yahoo
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-27 11:00 · Yahoo
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
2026-05-22 11:00 · Yahoo
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
2026-05-20 11:00 · Yahoo
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat
2026-05-19 11:00 · Yahoo
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
2026-04-28 11:00 · Yahoo
BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
2025-11-29 01:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.